PTC Therapeutics Inc. (PTCT)

The total asset value of PTC Therapeutics Inc. (PTCT) stood at $ 2,050 Mln as on 31-Mar-23

The share price of PTC Therapeutics Inc. (PTCT) is $21.48 (NASDAQ) as of 27-Nov-2023 16:00 EST. PTC Therapeutics Inc. (PTCT) has given a return of -30.33% in the last 3 years.

PTC Therapeutics Inc. (PTCT) has a market capitalisation of $ 3,295 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of PTC Therapeutics Inc. (PTCT) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PTC Therapeutics Inc. (PTCT) and enter the required number of quantities and click on buy to purchase the shares of PTC Therapeutics Inc. (PTCT).

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

The CEO & director of Dr. Stuart W. Peltz Ph.D.. is PTC Therapeutics Inc. (PTCT), and CFO & Sr. VP is Dr. Allan Steven Jacobson Ph.D..

The promoters of PTC Therapeutics Inc. (PTCT) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of PTC Therapeutics Inc. (PTCT) was $-571 Mln.